TAKE Solutions Ltd. announced the extension of its Safety and Pharmacovigilance services with the launch of SafetyReady for Oracle customers. The solution helps accelerate implementation for life sciences organizations looking to jumpstart Safety & Pharmacovigilance adoption efforts and operations planning in as little as five weeks. For small to medium-sized businesses with limited resources and staff constraints, TAKE offers SafetyReady Cloud, an on-demand option that provides easy deployment and maintenance of critical applications. TAKE’s SafetyReady suite also includes SafetyReady Upgrade and SafetyReady Migrate, modules to ease upgrades and migration to Oracle Argus Safety Suite.
TAKE’s SafetyReady solution includes the capabilities to help customers implement Oracle’s integrated platform for end-to-end pharmacovigilance solutions, from clinical development to post-marketing surveillance, ensuring regulatory compliance and comprehensive product oversight.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.